title: Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
abstract: OBJECTIVE
  To investigate oxaliplatin combined with fluorouracil-based chemoradiotherapy as preoperative treatment for locally advanced rectal cancer.
  
  
  METHODS
  Seven hundred forty-seven patients with resectable, locally advanced (cT3-4 and/or cN1-2) adenocarcinoma of the mid-low rectum were randomly assigned to receive pelvic radiation (50.4 Gy in 28 daily fractions) and concomitant infused fluorouracil (225 mg/m(2)/d) either alone (arm A, n = 379) or combined with oxaliplatin (60 mg/m(2) weekly × 6; arm B, n = 368). Overall survival is the primary end point. A protocol-planned analysis of response to preoperative treatment is reported here.
  
  
  RESULTS
  Grade 3 to 4 adverse events during preoperative treatment were more frequent with oxaliplatin plus fluorouracil and radiation than with radiation and fluorouracil alone (24% v 8% of treated patients; P < .001). In arm B, 83% of the patients treated with oxaliplatin had five or more weekly administrations. Ninety-one percent, compared with 97% in the control arm, received ≥ 45 Gy (P < .001). Ninety-six percent versus 95% of patients underwent surgery with similar rates of abdominoperineal resections (20% v 18%, arm A v arm B). The rate of pathologic complete responses was 16% in both arms (odds ratio = 0.98; 95% CI, 0.66 to 1.44; P = .904). Twenty-six percent versus 29% of patients had pathologically positive lymph nodes (arm A v arm B; P = .447), 46% versus 44% had tumor infiltration beyond the muscularis propria (P = .701), and 7% versus 4% had positive circumferential resection margins (P = .239). Intra-abdominal metastases were found at surgery in 2.9% versus 0.5% of patients (arm A v arm B; P = .014).
  
  
  CONCLUSIONS
  Adding oxaliplatin to fluorouracil-based preoperative chemoradiotherapy significantly increases toxicity without affecting primary tumor response. Longer follow-up is needed to assess the impact on efficacy end points.
authors: Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy. aschele@tin.it
authors: Carlo
authors: C
authors: Aschele
authors: Luca
authors: L
authors: Cionini
authors: Sara
authors: S
authors: Lonardi
authors: Carmine
authors: C
authors: Pinto
authors: Stefano
authors: S
authors: Cordio
authors: Gerardo
authors: G
authors: Rosati
authors: Salvatore
authors: S
authors: Artale
authors: Angiolo
authors: A
authors: Tagliagambe
authors: Giovanni
authors: G
authors: Ambrosini
authors: Paola
authors: P
authors: Rosetti
authors: Andrea
authors: A
authors: Bonetti
authors: Maria Emanuela
authors: ME
authors: Negru
authors: Maria Chiara
authors: MC
authors: Tronconi
authors: Gabriele
authors: G
authors: Luppi
authors: Giovanni
authors: G
authors: Silvano
authors: Domenico Cristiano
authors: DC
authors: Corsi
authors: Anna Maria
authors: AM
authors: Bochicchio
authors: Germana
authors: G
authors: Chiaulon
authors: Maurizio
authors: M
authors: Gallo
authors: Luca
authors: L
authors: Boni